Safety of expedited-surgery protocols in anticoagulant-treated patients with hip fracture: a systematic review and meta-analysis.

"Competing interests: Marc Carrier reports honoraria for speakers bureaus and support for attending meetings and/or travel from AbbVie, AngioDynamics, Anthos Therapeutics, AstraZeneca, Bayer, EOCI Pharmacomm, LEO Pharma, Pfizer, Sanofi, Servier Laboratories and Valeo Pharma. He has participated on data safety monitoring boards for the TRIM-Line study and the LIMIT Trial. He is president of Thrombosis Canada, was chair of the Thrombosis Canada Scientific Subcommittee, Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis in 2019, and was a member of the Guideline Panel of the American Society of Hematology in 2015–2021. Prism Schneider sits on the Scientific Advisory Council, Osteoporosis Canada and is chair of the Research Committee of the reimplementation of VKA Orthopaedic Trauma Association. No other competing interests were declared."

"We performed this systematic review using a predetermined study protocol registered with the International Prospective register of systematic reviews (PROSPERO) (CRD42020155306). The review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines."